The DEA hearing on proposed federal marijuana rescheduling is now underway, reopening one of the most consequential cannabis policy proceedings in decades.
According to the DEA announcement, proceedings are scheduled from June 29 through July 15, with each hearing day beginning at 9:00 a.m. ET. The agency has also indicated that transcripts will be made publicly available, creating a running public record for observers following the testimony.
A High-Stakes Procedural Phase
The current phase centers less on political messaging and more on evidentiary development before the Administrative Law Judge.
The hearing record is expected to shape how the proposal is evaluated, including how scientific, medical, and administrative arguments are weighed as the process moves forward.
Because transcript releases are expected throughout the hearing window, outside observers can assess witness claims and legal framing directly rather than relying only on summaries.
Participation Balance Is Under Scrutiny
The participant roster has become a controversy of its own.
While the DEA is responsible for presenting the government case in support of the rescheduling action, critics have argued that designated participants on the opposing side are overrepresented and that organizations advocating in favor of rescheduling were not selected as designated participants.
That imbalance concern does not resolve the legal merits by itself, but it has intensified debate over whether the hearing record will reflect a fully balanced adversarial presentation.
Louisiana Withdrawal Adds More Uncertainty
Another late procedural development came when Louisiana Attorney General Liz Murrill withdrew the state from litigation challenging the administration's rescheduling move.
No public explanation accompanied the withdrawal, and the timing has generated fresh speculation about litigation strategy and how broader state-level legal opposition may evolve as the hearing period proceeds.
What Comes Next
As testimony begins, attention now shifts from pre-hearing disputes to the evidentiary record itself.
If transcripts are published on a rolling basis as indicated, the public will be able to evaluate witness testimony and legal arguments in near real time. For a policy question with broad legal, medical, and commercial consequences, that visibility could become one of the most significant aspects of the hearing itself.
Update (Day Two)
Two days into the hearing, the government's strategy has become clearer. Rather than defending cannabis's placement in Schedule I, federal witnesses have emphasized accepted medical use, comparative safety, and the scientific findings supporting the proposed move to Schedule III. Opposing participants, by contrast, have concentrated on challenging that scientific and legal foundation.
The proceedings have also continued to draw scrutiny over participation, as many legalization advocates and industry representatives remain excluded from formally presenting evidence. So far, the debate has moved less toward whether cannabis has any medical value at all and more toward whether the government's existing findings justify extending Schedule III treatment beyond the medical framework federal policy has already recognized.